Hologic

587 articles with Hologic

• Hologic Completes Acquisition of Mobidiag

  6/17/2021

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

• Cigna Updates Medical Policy to Cover Hologic’s Acessa® Procedure, Expanding Access to Millions of Women Across the Country

  6/3/2021

  New Coverage Further Validates Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Standard of Care for Uterine Fibroids

• New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation

  5/24/2021

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that the American College of Obstetricians and Gynecologists (ACOG), in its updated guidance for Management of Symptomatic Uterine Leiomyomas , supports the use of laparoscopic radiofrequency ablation (Lap-RFA) for the trea

• Hologic and Partners Launch Project Health Equality to Help Transform the Care Women of Color Receive in the Health Care System

  5/11/2021

  Initiative Addresses Structural and Cultural Barriers to High-quality, Culturally Competent Health Care for Black and Hispanic Women; Delivers Innovative Health Research, Education and Access Model

• Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer

  5/10/2021

  More women gain access to a test that helps determine whether extended endocrine therapy is appropriate for them

• Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences - May 05, 2021

  5/5/2021

  Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

• Hologic Announces Financial Results for Second Quarter of Fiscal 2021

  4/28/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 27, 2021.

• Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

  4/8/2021

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has signed a definitive agreement to acquire Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million.

• Hologic to Announce Financial Results for the Second Quarter of Fiscal 2021 on Wednesday, April 28, 2021

  4/7/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2021 on Wednesday, April 28, after the market closes.

• Hologic Receives Gallup Exceptional Workplace Award

  3/22/2021

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has been named a winner of the 2021 Gallup Exceptional Workplace Award, the Company announced today.

• Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million

  3/1/2021

  -- Transaction Expands and Diversifies Hologic’s Diagnostic Business Across Test Menu, Customer Segments and Geography –

• Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

  2/22/2021

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million.

• New Research Published in the Journal of the American College of Radiology Confirms Black Women More Likely to Receive Inferior Breast Cancer Screening Than White Women, Points to Need for Stronger Breast Health Equity Reform

  2/19/2021

  Review of more than 800,000 mammograms reveals Black women less likely to be screened via digital breast tomosynthesis, despite the technology being proven superior to traditional mammography for all women

• Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

  2/10/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:

• Hologic’s New Sustainability Report Highlights How the Company’s Purpose-Driven Culture is Making a Unique Difference in the World

  2/4/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today the on-line publication of its 2020 sustainability report, “The Power of Purpose.”

• Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities

  2/1/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today a multi-year strategic collaboration with Google Cloud that will feature the integration of Google Cloud’s machine learning (ML) technologies with Hologic’s cutting-edge Genius™ Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe.

• Hologic Announces Financial Results for First Quarter of Fiscal 2021

  1/27/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 26, 2020.

• Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021

  1/8/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 26, 2020.

• Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021

  1/8/2021

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2021 on Wednesday, January 27, after the market closes.

• Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

  1/5/2021

  – Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth –